Advice
in the absence of a submission from the holder of the marketing authorisation:
cobimetinib (Cotellic®) is not recommended for use within NHS Scotland.
Indication under review: in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- cobimetinib (Cotellic)
- SMC ID:
- 1191/16
- Indication:
- In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 September 2016